ARQT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcutis Biotherapeutics Inc (ARQT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 investment capacity. The stock shows potential for growth based on technical indicators, positive congressional trading sentiment, and a favorable price target from analysts. Despite insider selling, the stock's technical strength and congressional interest make it a suitable long-term investment.
The MACD histogram is 0.561, above 0, and positively contracting, indicating bullish momentum. The RSI is at 86.69, signaling an overbought condition, but this could suggest strong demand. Moving averages are converging, indicating potential consolidation or a breakout. Key support is at 24.046, with resistance at 26.34 and 27.757, suggesting the stock is near its resistance level.
Congressional trading data shows a recent purchase transaction in the $0.1M to $1.5M range, indicating confidence from influential figures. Analysts maintain an Overweight rating with a price target of $34, suggesting significant upside potential.
Insiders have increased selling activity by 106.52% over the last month, which could indicate caution from those within the company. RSI indicates overbought conditions, which might lead to short-term price corrections.
No financial data available for the latest quarter.
Morgan Stanley recently lowered the price target slightly from $35 to $34 but maintained an Overweight rating, reflecting continued confidence in the stock's long-term potential.
